Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific share repurchase transaction executed on July 20, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,270,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,333.0 pence per share; lowest price paid was 1,321.0 pence per share.
- Treasury Holdings (Settled): 485,084,284 shares (8.66% of total issued share capital).
- Treasury Holdings (Including Unsettled): 489,154,284 shares (9.56% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,118,408,950 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,270,000 shares. This transaction increased the proportion of shares held in Treasury to 8.66% of issued capital and 9.56% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The stated intent is to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total cost of the 1,270,000 shares purchased based on the weighted average price between 1,321.0 and 1,333.0 pence.
- Confirm the impact of the 9.56% treasury holding on total voting rights calculations for major shareholders.
- Check subsequent filings for the settlement status of the 4,070,000 shares included in the "purchased but not yet settled" figure.
- Review the remaining authorization limit for share buybacks under the May 5, 2011 shareholder mandate.